The Impact of the Drug Quality and Security Act on Compounding Pharmacies Is the Subject of May 13th Seminar in Boston
AGAWAM,
MASS. — April 29, 2014 — A seminar focusing on the impact of HR3204 — the Drug Quality and Security Act — on compound pharmacies
and manufacturers is the subject of a seminar set for May 13, 2014 in Dedham,
Mass., near Boston.
Meeting
the new guidelines will require substantial changes for many compounders. The
seminar is designed to explain the stepping stones needed to comply with the
new legislation as well as review USP <797> in its current state. 797>
The
seminar will provide pharmacies and compounders that do business as compounding
manufacturers and outsourcing facilities with the knowledge they need to know
about how the new regulatory expectations will affect their businesses.
Seminar topics will include:
·
Becoming a compounding manufacturer
·
Manufacturing under cGMP requirements
·
Meeting current USP <797> requirements 797>
The seminar will
be presented by Microtest Laboratories, a leader in testing services for the
medical device, pharmaceutical, and biotechnology industries, on Tuesday, May 13, 2014, from 9 a.m. to 3 p.m. at the Endicott House in Dedham, Mass., just outside Boston. Registration
is at 8:30 a.m. A continental breakfast, break
refreshments, and a luncheon are included.
To register, visit http://www.microtestlabs.com/seminar or contact Julie Adamski 1-800-631-1680, ext. 192, or jadamski@microtestlabs.com. Advance registration is $149.
About Microtest Laboratories
Microtest
Laboratories is a leader in testing services for the medical device,
pharmaceutical, and biotechnology industries. Based in Agawam, Massachusetts,
USA, the company provides expertise and flexible processes that enhance product
safety and security, accelerate time to market, and minimize supply chain
disruption. For more information, visit http://www.microtestlabs.com or call 1-413-786-1680 or toll-free 1-800-631-1680. Follow
Microtest Laboratories on Facebook at http://facebook.com/MicrotestLaboratories, on LinkedIn at http://goo.gl/H8ZLnM or on Twitter @MicrotestLabs.
Labels: cGMP, compounding manufacturer, compounding pharmacies, compounding pharmacy, Drug Quality and Security Act, HR3204, USP <797>
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home